Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-371 added to hypertonic saline in cystic fibrosis patients receiving Orkambi
2015-004841-13Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-371 sequence with Placebo sequence (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2016; status: completed.
02
Drugs
idrevloride
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-004841-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004841-13.